Immunovaccine Inc.

  • HEALTH CARE - Pharmacy
  • GROWTH CHAMPIONS
1344 Summer St.
Suite 412
Halifax, NS B3H 0A8
(902) 492-1819
(902) 492-0888 (fax)

About Us

Immunovaccine Inc. is a clinical-stage biopharmaceutical corporation dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and read more
  • About

    Immunovaccine Inc. is a clinical-stage biopharmaceutical corporation dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops T cell activating cancer immunotherapies and infectious disease vaccines based on DepoVax™, the Corporation’s patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The Corporation is also exploring additional applications of DepoVax™, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects to assess the potential of its platform to address malaria and the Zika virus. Connect at www.imvaccine.com.

  • Media

  • Whom to Contact

    • Hailey Dewtie
      Office Assistant
      Phone: (902) 492-1819
    • Anna Fryday
      HR Associate
      Phone: (902) 492-1819 ext 27

    Stay Connected

    Sign-up to receive important updates on Halifax Chamber events, Member benefits and advocacy news.